MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

TG Therapeutics Inc

Chiusa

SettoreSettore sanitario

29.72 -2.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.61

Massimo

30.51

Metriche Chiave

By Trading Economics

Entrata

363M

391M

Vendite

21M

162M

P/E

Media del settore

11.235

78.892

Margine di Profitto

241.727

Dipendenti

374

EBITDA

-4.9M

33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+40.85% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-405M

4.9B

Apertura precedente

32.28

Chiusura precedente

29.72

Notizie sul Sentiment di mercato

By Acuity

50%

50%

151 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

TG Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 dic 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

WiseTech to Sell Expedient to Appease Competition Regulator

30 dic 2025, 17:12 UTC

I principali Market Mover

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 dic 2025, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 dic 2025, 21:08 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 dic 2025, 20:41 UTC

Discorsi di Mercato

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 dic 2025, 20:37 UTC

Utili

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 dic 2025, 19:29 UTC

Discorsi di Mercato

Corn Extends Pullback in Light Trade -- Market Talk

30 dic 2025, 18:29 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

30 dic 2025, 16:20 UTC

Utili

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 dic 2025, 16:18 UTC

Acquisizioni, Fusioni, Takeovers

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 dic 2025, 16:10 UTC

Discorsi di Mercato

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 dic 2025, 15:24 UTC

Discorsi di Mercato

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 dic 2025, 15:10 UTC

Acquisizioni, Fusioni, Takeovers

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 dic 2025, 14:24 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 dic 2025, 14:22 UTC

Acquisizioni, Fusioni, Takeovers

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 dic 2025, 14:20 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 dic 2025, 14:17 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 dic 2025, 14:16 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 dic 2025, 14:14 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 dic 2025, 14:12 UTC

Acquisizioni, Fusioni, Takeovers

LVMH: Les Editions Croque Futur Is a French Publishing House

30 dic 2025, 14:10 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Acquires Les Editions Croque Futur

30 dic 2025, 13:49 UTC

Acquisizioni, Fusioni, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 dic 2025, 13:36 UTC

Discorsi di Mercato

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 dic 2025, 13:30 UTC

Discorsi di Mercato

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 dic 2025, 12:55 UTC

Discorsi di Mercato

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 dic 2025, 11:55 UTC

Discorsi di Mercato
Utili

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 dic 2025, 11:47 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 dic 2025, 11:35 UTC

Acquisizioni, Fusioni, Takeovers

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Confronto tra pari

Modifica del prezzo

TG Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.85% in crescita

Previsioni per 12 mesi

Media 43 USD  40.85%

Alto 60 USD

Basso 13 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TG Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

3

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 34.86Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

151 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat